Gibson, Dunn & Crutcher advised Jade Biosciences on the transaction, and Cooley advised the placement agents; while Goodwin Procter advised Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc....
Jade Biosciences’ Merger with Aerovate Therapeutics
MBX Biosciences’ $187.7 Million IPO
Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
AVROBIO’s Merger with Tectonic Therapeutic
Leerink Partners is serving as exclusive financial advisor to Tectonic and Cooley LLP is serving as legal counsel to Tectonic. Leerink Partners and TD Cowen are...
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
Amphastar Pharmaceuticals’ $345 Million Convertible Senior Notes Offering
Goodwin advised the initial purchasers on Amphastar Pharmaceuticals, Inc.’s offering. Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the Rule 144A offering of 2.00% Convertible Senior Notes due...
Novo Nordisk’s $1.3 Billion Acquisition of Ocedurenone
KBP Biosciences was represented by Goodwin Procter LLP and Novo Nordisk was represented by Covington & Burling LLP in this transaction. Novo Nordisk A/S and KBP...
Coherus’ Acquisition of Surface Oncology
Arnold & Porter advised Coherus Biosciences Inc. on the deal, and Goodwin advised Surface Oncology. Coherus Biosciences Inc. (Coherus) announced its acquisition of Surface Oncology Inc. (Surface),...
SunMed’s $110 Million Acquisition of Avanos’ Respiratory Health Business
Goodwin Procter is serving as legal counsel to SunMed, and Alston & Bird is serving as legal counsel to Avanos. SunMed announced it has entered into...
GreenLight Biosciences Holdings’ Go-Private Transaction
Goodwin Procter advised GreenLight Biosciences, Foley Hoag advised the Special Committee, while O’Melveny & Myers advised Fall Line on the deal. GreenLight Biosciences Holdings, PBC (NASDAQ:...
FibroGen’s $150 Million Financing with Morgan Stanley Tactical Value
Goodwin Procter acted as counsel to FibroGen, and Gibson Dunn acted as counsel to Morgan Stanley Tactical Value. FibroGen, Inc. (NASDAQ: FGEN) announced a non-dilutive term...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
PointClickCare’s Acquisition of Patient Pattern
Goodwin Procter advised PointClickCare Corp. on the deal. PointClickCare Corp. announced its acquisition of Patient Pattern. The combination of PointClickCare and Patient Pattern will further the companies’...